T. Schubbert

Rational and successful use of carboplatin and albumin-bound paclitaxel in a patient with recurrent metaplastic carcinoma who presented with multi-organ tumor emboli.

R. Mehta, P. Carpenter, T. Schubbert, 2009, Clinical breast cancer.

Trastuzumab in inflammatory breast cancer.

R. Mehta, K. Kong, T. Schubbert, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Metronomic schedule of paclitaxel is effective in hormone receptor-positive and hormone receptor-negative breast cancer.

R. Mehta, D. Jackson, T. Schubbert, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

beta-Carotene treatment of cervical intraepithelial neoplasia: a phase II study.

M. Schell, S. Liao, Y. Peng, 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Weekly carboplatin and nab-paclitaxel plus trastuzumab, or plus or minus bevacizumab: Clinical response in patients with breast cancer.

R. Mehta, K. Kong, T. Schubbert, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term outcome of phase II study of biweekly dose-dense AC followed by weekly paclitaxel and carboplatin and trastuzumab (TC {+/-} H) based on HER2 status in large and inflammatory breast cancer (BC).

R. Mehta, D. Jackson, T. Schubbert, 2010 .

Re: HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.

R. Mehta, T. Schubbert, 2008, Journal of the National Cancer Institute.